IDEAYA Biosciences (IDYA) Receivables (2020 - 2026)

IDEAYA Biosciences has reported Receivables for 7 years, with the latest figure at $13.1 million in Q1 2026.

• Quarterly Receivables changed N/A year-over-year to $13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (changed N/A YoY) and the FY2025 annual result came in at $11.9 million, up 398100.0% from the prior year.
• Receivables climbed to $13.1 million in Q1 2026 per IDYA's latest filing, from $11.9 million in the prior quarter.
• Over five years, Receivables peaked at $13.1 million in Q1 2026 and troughed at $1000.0 in Q2 2024.
• A 5-year average of $2.6 million and a median of $244000.0 in 2022 frame the typical range for Receivables.
• The sharpest annual moves came in 2024 and 2025: Receivables plunged 99.7% in 2024, then jumped 398100.0% in 2025.
• Over 5 years, Receivables stood at $200000.0 in 2022, then plunged by 91.0% to $18000.0 in 2023, then plunged by 83.33% to $3000.0 in 2024, then surged by 398100.0% to $11.9 million in 2025, then climbed by 9.83% to $13.1 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $13.1 million, $11.9 million, and $3000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.